- Home
- PDT vs XNCR Comparison
PDT vs XNCR Comparison
Compare PDT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDT
- XNCR
- Stock Information
- Founded
- PDT 1989
- XNCR 1997
- Country
- PDT United States
- XNCR United States
- Employees
- PDT N/A
- XNCR N/A
- Industry
- PDT Finance Companies
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- PDT Finance
- XNCR Health Care
- Exchange
- PDT Nasdaq
- XNCR Nasdaq
- Market Cap
- PDT 627.1M
- XNCR 579.3M
- IPO Year
- PDT N/A
- XNCR 2013
- Fundamental
- Price
- PDT $13.10
- XNCR $9.65
- Analyst Decision
- PDT
- XNCR Buy
- Analyst Count
- PDT 0
- XNCR 8
- Target Price
- PDT N/A
- XNCR $29.29
- AVG Volume (30 Days)
- PDT 145.6K
- XNCR 956.4K
- Earning Date
- PDT 01-01-0001
- XNCR 08-04-2025
- Dividend Yield
- PDT 8.88%
- XNCR N/A
- EPS Growth
- PDT N/A
- XNCR N/A
- EPS
- PDT N/A
- XNCR N/A
- Revenue
- PDT N/A
- XNCR $127,228,000.00
- Revenue This Year
- PDT N/A
- XNCR N/A
- Revenue Next Year
- PDT N/A
- XNCR $29.35
- P/E Ratio
- PDT N/A
- XNCR N/A
- Revenue Growth
- PDT N/A
- XNCR N/A
- 52 Week Low
- PDT $8.77
- XNCR $7.16
- 52 Week High
- PDT $13.05
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- PDT 60.73
- XNCR 59.62
- Support Level
- PDT $13.01
- XNCR $8.76
- Resistance Level
- PDT $13.23
- XNCR $9.60
- Average True Range (ATR)
- PDT 0.17
- XNCR 0.52
- MACD
- PDT 0.02
- XNCR 0.29
- Stochastic Oscillator
- PDT 80.88
- XNCR 90.87
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest growth of capital. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.